GLP-1 Weight-Loss Drugs Linked to Lower Breast Cancer Risk, Prompting New Trials

New observational studies presented at ASCO suggest GLP-1 medications used for diabetes and weight loss (e.g., semaglutide, liraglutide) are associated with a lower incidence of breast cancer and, among those diagnosed, reduced progression and mortality. While promising, the studies cannot prove causation, and researchers are planning randomized trials to test whether GLP-1 drugs can help prevent breast cancer or improve outcomes in high-risk individuals.